查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1703446

依托昔布市場－全球產業規模、佔有率、趨勢、機會和預測，按銷售管道、最終用途、地區和競爭細分，2020-2030 年

Etoricoxib Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球依托昔布市值為 1.1078 億美元，預計到 2030 年將達到 2.7144 億美元，預測期內年複合成長率(CAGR) 為 12.06%。這個市場正在經歷持續成長，主要原因是對有效抗發炎治療的需求不斷成長，以及骨關節炎、類風濕性關節炎和慢性疼痛等疾病的盛行率不斷上升。

市場概覽
預測期 2026-2030
2024年市場規模 1.1078億美元
2030年市場規模 2.7144億美元
2025-2030 年複合年成長率 12.06%
成長最快的領域 直接的
最大的市場 亞太

依托昔布是一種選擇性環氧合酶-2 (COX-2) 抑制劑，廣泛用於治療與這些疾病相關的疼痛和發炎。作為一種非類固醇抗發炎藥物 (NSAID)，它因具有針對性的作用機製而受到青睞，這降低了通常與傳統 NSAID 相關的胃腸道副作用的可能性。透過選擇性抑制 COX-2 而不是 COX-1，依托昔布為疼痛和發炎管理提供了更精確的方法。這種藥理優勢使其特別適合長期使用，尤其是老年患者或有胃腸道併發症病史的患者。其良好的安全性繼續推動醫療專業人員和患者的採用。

關鍵市場促進因素

全球醫療保健產業的成長

主要市場挑戰

供應鏈漏洞

主要市場趨勢

強調有針對性的疼痛緩解

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球依托昔布市場的影響

第5章：全球依托昔布市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按銷售管道（直接、間接）
    • 依最終用途（骨關節炎、類風濕性關節炎、僵直性脊椎炎、急性痛風性關節炎、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美依托昔布市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲依托昔布市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太依托昔布市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲依托昔布市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲依托昔布市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：全球依托昔布市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Orex Pharma
  • Aurore Life Sciences
  • Hetero
  • Aoki Medicinal
  • Guangdong Raffles Pharma Tech Co.,Ltd
  • Sichuan Yujian Pharmaceutical Co., Ltd
  • Gennex Laboratories Limited
  • Cipla Limited
  • MICRO LABS LIMITED
  • Greenkem Organics Pvt Ltd

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 28285

Global Etoricoxib Market was valued at USD 110.78 million in 2024 and is projected to reach USD 271.44 million by 2030, growing at a compound annual growth rate (CAGR) of 12.06% during the forecast period. This market is experiencing consistent growth, primarily driven by the rising demand for effective anti-inflammatory treatments and the increasing prevalence of conditions such as osteoarthritis, rheumatoid arthritis, and chronic pain disorders.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 110.78 Million
Market Size 2030USD 271.44 Million
CAGR 2025-203012.06%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is widely used for the management of pain and inflammation associated with these medical conditions. As a nonsteroidal anti-inflammatory drug (NSAID), it is preferred due to its targeted mechanism of action, which reduces the likelihood of gastrointestinal side effects typically associated with conventional NSAIDs. By selectively inhibiting COX-2 rather than COX-1, etoricoxib offers a more precise approach to pain and inflammation management. This pharmacological advantage makes it particularly suitable for long-term use, especially among elderly patients or those with a history of gastrointestinal complications. Its favorable safety profile continues to drive adoption among both healthcare professionals and patients.

Key Market Drivers

Growth of the Global Healthcare Industry

The global expansion of the healthcare sector is a significant factor contributing to the increased demand for etoricoxib. As a selective COX-2 inhibitor, etoricoxib is widely recognized for its analgesic and anti-inflammatory properties. The healthcare industry, one of the fastest-growing economic sectors worldwide, accounts for more than 10% of GDP in many developed economies. For instance, healthcare spending in the United States rose by 2.7% in 2021, reaching USD 4.3 trillion, or approximately USD 12,914 per capita.

With ongoing improvements and expansion in healthcare systems-particularly across emerging markets-the demand for effective pain management solutions has surged. Etoricoxib's ability to treat chronic conditions such as osteoarthritis, rheumatoid arthritis, and acute pain positions it as a valuable addition to modern, patient-centered treatment plans.

Key Market Challenges

Supply Chain Vulnerabilities

The production of etoricoxib depends on the availability of pharmaceutical-grade raw materials and intermediate compounds. Disruptions in the supply chain-whether due to bottlenecks, regulatory restrictions, or volatility in raw material prices-can significantly delay manufacturing and impact product availability. For example, shortages or cost increases in essential inputs may lead to elevated production costs, reducing profit margins or resulting in higher prices for end-users.

Geopolitical factors such as trade disputes, tariffs, and regional instability further complicate global supply chains. Given that etoricoxib manufacturers typically depend on a network of international suppliers and contract manufacturers, any disruption-whether due to customs delays, export restrictions, or geopolitical conflict-poses a substantial risk. These challenges are particularly critical in the pharmaceutical industry, where timely access to medications is essential for patient care.

Key Market Trends

Emphasis on Targeted Pain Relief

A growing trend in the global etoricoxib market is the increasing emphasis on targeted pain management, especially in the context of chronic pain and inflammation. Etoricoxib, as a selective COX-2 inhibitor, is approved for short-term relief of moderate post-operative dental pain and for treating pain and inflammation associated with various forms of arthritis.

With the healthcare industry shifting toward precision medicine, there is a heightened focus on therapies that provide safer, more personalized, and more effective treatment outcomes. Etoricoxib is gaining traction due to its ability to precisely target pain and inflammatory pathways while minimizing the adverse effects typically linked to traditional NSAIDs.

Unlike non-selective NSAIDs that inhibit both COX-1 and COX-2 enzymes, etoricoxib's selective inhibition of COX-2 is associated with a lower risk of gastrointestinal and cardiovascular complications. This makes it an attractive option for long-term pain management, particularly in older adults and patients with preexisting health conditions.

Key Market Players

  • Orex Pharma
  • Aurore Life Sciences
  • Hetero
  • Aoki Medicinal
  • Guangdong Raffles Pharma Tech Co.,Ltd
  • Sichuan Yujian Pharmaceutical Co., Ltd
  • Gennex Laboratories Limited
  • Cipla Limited
  • MICRO LABS LIMITED
  • Greenkem Organics Pvt Ltd

Report Scope

In this report, the Global Etoricoxib Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Etoricoxib Market, By Sales Channel:

  • Direct
  • Indirect

Etoricoxib Market, By End Use:

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Acute Gouty Arthritis
  • Others

Etoricoxib Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Etoricoxib Market.

Available Customizations:

Global Etoricoxib Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Etoricoxib Market

5. Global Etoricoxib Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Etoricoxib Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Etoricoxib Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Etoricoxib Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Etoricoxib Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Etoricoxib Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Etoricoxib Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Etoricoxib Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Etoricoxib Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Etoricoxib Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Etoricoxib Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Etoricoxib Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Etoricoxib Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Etoricoxib Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Etoricoxib Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Etoricoxib Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Etoricoxib Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Etoricoxib Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Etoricoxib Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Etoricoxib Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Etoricoxib Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Etoricoxib Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Etoricoxib Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Etoricoxib Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Etoricoxib Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Etoricoxib Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Orex Pharma
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Aurore Life Sciences
  • 15.3. Hetero
  • 15.4. Aoki Medicinal
  • 15.5. Guangdong Raffles Pharma Tech Co.,Ltd
  • 15.6. Sichuan Yujian Pharmaceutical Co., Ltd
  • 15.7. Gennex Laboratories Limited
  • 15.8. Cipla Limited
  • 15.9. MICRO LABS LIMITED
  • 15.10. Greenkem Organics Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer